They’re Trying to Crucify Guru Ameen for Healing People: Stanford Just Proved He Was Right

Where We Are Now

In June 2023 I wrote the first article on my relationship with ibogaine and my friend guru ameen Alai. A lot has happened in fifteen months.

First, the prediction I made in that article came true. Federal prosecutors, facing an autopsy report that documented pre-existing sepsis from a post-surgical infection, an enlarged heart “three times the size of normal,” restricted blood flow, cirrhosis, and a coroner’s report that listed multiple contributing factors, dropped the “distribution resulting in death” enhancement against Ameen. That enhancement carried a mandatory minimum of 20 years in federal prison. It collapsed because the government could not meet the sole-cause-of-death standard. If you’re a bettor — and I’ve been betting on biochemistry for two decades — you would call that an admission the underlying causation case was weak.

The broader distribution charge is still pending. The government is now trying to convict Ameen for handing out a Schedule I substance, full stop. Different legal standard. Different consequences. The defense — led by the McBride Law Firm and, in the last few months, supplemented by contributions from Andrew and Tristan Tate — is still fighting. And Ameen, whose income has been destroyed by the indictment and whose reputation has been deliberately smeared by leaks to the press, is now relying on a public defender framework that, in my honest read, is angling him toward a plea deal he should not take.

I want to update you on what’s happened outside the courtroom too, because the contrast between Ameen’s prosecution and the broader cultural moment around ibogaine is, at this point, absurd.

The Stanford Data That Should End This Debate

In November 2023, Nature Medicine — the most prestigious medical journal on earth — published the Stanford study on ibogaine and 5-MeO-DMT treatment of Special Operations veterans at a clinical facility in Mexico.

The numbers:

• 88% reduction in PTSD symptoms on standardized clinical scales at one-month follow-up.
• 87% reduction in depression symptoms.
• 81% reduction in anxiety.
• Significant improvements in cognitive functioning — executive function, concentration, reaction time.
• No serious adverse cardiac events in a population that was cardiac-screened beforehand.

These numbers are, to put it mildly, without precedent. No SSRI trial in the history of pharmacology has produced remission numbers like this in combat-PTSD populations. Conventional first-line PTSD treatment produces meaningful symptom reduction in roughly 30-50% of patients, with high rates of chronic relapse. Ibogaine, in a single flood-dose session, outperforms every pharmaceutical on the market by a factor of 2 or more.

The study was published. The veterans it documented are public about their results. Multiple of them have testified before congressional committees. This is not fringe data. This is peer-reviewed, institutional, and it is the exact molecule my friend Ameen is being prosecuted for handing to Americans who cannot afford to fly to Mexico.

The Political Coalition No One Saw Coming

Watching the political landscape move on this in real time has been one of the more surreal experiences of the last year. Here’s the current state of play:

Rick Perry — former Secretary of Energy under Trump, former Governor of Texas — has publicly stated he is “dedicating his life” to promoting ibogaine. He is actively lobbying the Texas legislature to allocate $50 million in state funds to ibogaine clinical trials for veterans and people battling addiction. The bill is advancing. Perry has called ibogaine “a miracle.” On the record.

Robert F. Kennedy Jr. — currently running for president as an independent — has posted repeatedly on X about his intent to legalize “all psychedelic medicines” including ibogaine if elected. He has been vocal that the fda and pharmaceutical industry are blocking addiction solutions because the existing pharmaceutical addiction-treatment market is worth roughly $78.5 billion per year, and Big Pharma has no financial incentive to cure what it can manage chronically.

Rep. Dan Crenshaw — Republican congressman, former Navy SEAL — authored and passed legislation signed into law in December 2023 directing the Department of Defense to research psychedelics, including ibogaine, for PTSD and TBI in active-duty service members. A Navy SEAL wrote the law. Elite American soldiers are federally authorized to receive ibogaine research treatment. My friend is facing federal prison for providing it to civilians.

Lt. Gen. Jack Bergman — Republican congressman, retired Marine Corps three-star general, highest-ranking military veteran in Congress — co-chairs the Congressional Psychedelics Advancing Therapies (PATH) Caucus. He has publicly stated that conventional pharmaceutical treatment for veteran PTSD “doesn’t work” and that ibogaine research must be expanded to stop the veteran suicide crisis.

W. Bryan Hubbard — former chair of the Kentucky Opioid Abatement Advisory Commission — attempted to allocate $42 million of opioid settlement funds to ibogaine research in 2023. He was blocked politically but has since become one of the loudest public advocates on the podcast circuit, including multiple appearances on Joe Rogan’s show where he has walked through the per-dollar efficacy of ibogaine vs. every FDA-approved addiction treatment.

Joe Rogan — somehow still the most influential podcaster in the country — has discussed ibogaine on his show dozens of times, has brought veterans who credit it with saving their lives into the studio, and has publicly said he has personally considered it.

Read that coalition again. A Trump cabinet member. A Democratic presidential candidate. A Navy SEAL Republican congressman. A Marine three-star general. A Kentucky Republican commissioner. The most-listened-to podcaster on earth. This is not a fringe coalition. This is the political center of gravity of American drug policy, and every one of them is saying — in public, on the record — exactly what Ameen has been saying for a decade.

And my friend sits under federal indictment.

The Noribogaine Patent Play — Why the System Is Terrified of the Natural Plant

Here’s the part of this story the mainstream press is afraid to cover because it would implicate their largest advertisers.

Ibogaine, as a naturally occurring alkaloid, cannot be patented. Patent law in the United States does not grant exclusivity on substances that occur in nature. The iboga root has been used in Bwiti spiritual ceremonies in Gabon for centuries. You cannot own it.

Its active metabolite — noribogaine — is a different story. Noribogaine has a longer half-life (28-49 hours) and a somewhat different receptor profile. Because it can be synthesized in a lab rather than extracted from a plant, it can be treated as a novel chemical entity. You can patent noribogaine. Several pharmaceutical development companies — including ATAI Life Sciences, DemeRx, and others — currently hold or are filing patents on noribogaine, 18-MC (a non-cardiotoxic ibogaine analog), and related synthetic derivatives.

This creates an obvious economic incentive structure. If the natural ibogaine plant becomes medically and culturally accepted, anyone can grow iboga and extract ibogaine. No pharmaceutical company can monopolize it. If instead the regulatory pathway leads to FDA approval of synthetic noribogaine as a branded pharmaceutical, the entire patient population funnels into a patent-protected drug at $10,000-$50,000 per treatment course, and the pharmaceutical companies that own the patents make billions.

The race is on. And the critical strategic problem for the patent-holders is this: if the natural plant is too visible, too culturally normalized, too accessible through underground practitioners like Guru Ameen, the patent-protected synthetic doesn’t have the market to itself.

This is the economic structure the Ameen prosecution makes sense inside. He isn’t being prosecuted as punishment for a death. He’s being prosecuted as a warning shot — do not operate in the natural-plant space, because we will make an example of you. The DEA, the fda, and the DOJ all answer to political pressure that is ultimately shaped by the industries those agencies regulate. Pharma has a pipeline to protect. Ameen is in the way.

The tony huge Laws of Biochemistry Physics — Law 4 Applied

Law 4 of the tony huge Laws of Biochemistry Physics: Self-Regulating Systems. The body fights to maintain homeostasis. Push a system one direction and feedback mechanisms push back. Exogenous testosterone suppresses natural production via HPG-axis downregulation. Smart protocol design anticipates counter-regulation and either works with it (pulsing, cycling) or blocks it (ancillaries, SERMs).

Addiction is a homeostatic system in a hijacked set-point. The body has reorganized its entire neurochemistry around the expected presence of the substance. Pull the substance abruptly and the homeostatic counter-regulation produces withdrawal — dopamine crash, glutamate rebound, HPA axis firestorm, sleep collapse. That counter-regulation is precisely what keeps the cycle alive.

Every FDA-approved addiction medication works with the hijacked homeostasis. Suboxone (buprenorphine + naloxone) partially occupies the mu-opioid receptor at a lower intensity — it prevents the crash but preserves the set-point. Methadone does the same with higher intensity. Naltrexone blocks the mu-opioid receptor entirely but does nothing to rebuild the damaged dopaminergic circuitry. All three create a new homeostatic equilibrium with the patient on the drug. This is exactly what Big Pharma’s business model requires: lifelong subscription-model patients.

Ibogaine does the opposite. A single flood dose does two things simultaneously:

1. It occupies the mu-opioid receptor (weak agonism) in a way that neutralizes withdrawal while the patient is going through the session — so the counter-regulation doesn’t get its voice.
2. It upregulates GDNF via noribogaine, which physically regenerates the damaged dopaminergic neurons. The homeostatic set-point itself shifts back toward pre-addicted baseline.

The patient comes out the other side of a 12-hour session with withdrawal suppressed AND the circuitry rebuilt. No counter-regulation chase. No maintenance prescription. Law 4 bypassed through a combination move no other single molecule on earth can replicate.

This is why ibogaine is the existential threat. Not because it’s dangerous. Because it works, in one session, without creating a lifetime patient.

The Year of Microdose — What I’ve Learned

Over the last 15 months I’ve continued my microdose protocol under Ameen’s supervision. I’ve varied the dose, tracked HRV and resting heart rate via my Oura ring, logged mood and sleep, and kept a journal that is now thick enough to be a small book.

Key learnings I can share:

The effect compounds slowly. The first month is subtle. By month three you notice the absence of certain mental patterns — compulsive scrolling, late-night food cravings, the kind of low-grade anxious baseline most of us think is normal. It is not. It turns out it’s the governor running, and ibogaine microdose is quietly loosening it.

The sleep architecture change is profound. I went from chronic 6-hour nights with fragmented REM to consistent 7.5-8 hour nights with dramatically more REM. If you know anything about how GDNF and BDNF are implicated in sleep-dependent memory consolidation, this makes biochemical sense. Better sleep drove a cascade of downstream improvements I wasn’t even targeting.

The emotional calibration is the big one. I described this last year as feeling “settled.” Fifteen months in, I’d rather describe it as reconnected to a baseline emotional responsiveness I hadn’t realized I’d lost. Life feels more vivid. I don’t know how else to describe it.

Cardiac baseline has been stable throughout. I run quarterly EKGs at Ameen’s insistence. QTc has been rock-steady. No arrhythmias. No concerning changes. The safety protocol he has me on is rigorous, and rigor is what separates the people who do this right from the people who get hurt.

Full flood dose is still on my horizon. I am not yet in a life circumstance where the 12-hour oneirogenic session fits cleanly into my schedule, and Ameen is being — appropriately — patient about it. When I do go through with it, it will be under his supervision, not in any hospital or clinic staffed by MDs who have never personally taken the molecule. That choice is not up for debate.

Why I Trust Ameen Over Any MD

A doctor with seven years of conventional training and zero personal ibogaine experience is less qualified to supervise my session than Ameen is. That sentence is going to upset some people. It shouldn’t.

The practitioners with the deepest knowledge of this molecule are the ones who have taken it themselves, supervised others through sessions, observed edge cases, and built protocol wisdom across years of direct exposure. American medical education does not teach ibogaine. It cannot — ibogaine is Schedule I. The MDs who do know this molecule know it because they broke the law to learn it, or because they left the United States to practice it, or because they are the handful of researchers with DEA Schedule I licenses, of which there are vanishingly few.

Ameen has supervised hundreds of sessions. He has a personal recovery history. He reads every paper published on this compound. He walked me through my cardiac screening process with more rigor than most cardiologists I’ve met. He is the person I want in the room when I step into a 12-hour neurochemical reset. Anyone with the humility to evaluate credentials based on relevant expertise rather than on institutional pedigree will understand exactly why.

I’ve known the man for seven years. He’s earned that trust the hard way.

What Needs to Happen Now

Three tracks.

Track 1: The Ameen defense. The “resulting in death” charge is gone. The underlying distribution charge is still live. The defense needs resources. If you have the means, contribute to his legal fund. If you have a platform, talk about the case. If you have contacts in veterans’ advocacy, in medical freedom, in harm-reduction — connect them. The attempt to plea-deal him into a conviction he does not deserve is an active threat, and pressure matters.

Track 2: Political. Perry, RFK, Crenshaw, Bergman, Hubbard, Rogan — these are the loudest voices right now, but the quiet supporters in state legislatures are what will break this open. Texas is leading. Kentucky is the next battleground. Colorado’s ibogaine-specific framework is being built as we speak. If you live in a state with a psychedelic reform conversation happening, show up.

Track 3: Educational. Every time you share the Stanford veteran data with someone who still thinks this is fringe hippie medicine, you move the Overton window. The coalition is forming. The culture is behind. Close the gap.

I’ll be writing again. The case will resolve one way or the other — I expect a plea deal the defense will have no option to decline, given the resource asymmetry, but I’ve been wrong about federal cases before. If they actually let this go to a jury, the forensic weakness of the case is going to be very hard to overcome. Either way, the broader ibogaine story is only accelerating.

FAQ

What is the current legal status of the Ameen Alai federal case in September 2024?

The “distribution resulting in death” enhancement (carrying a mandatory minimum of 20 years) was dropped by federal prosecutors, validating defense arguments that the underlying autopsy did not support a sole-cause-of-death finding. The lesser distribution charge is still pending. Defense is led by the McBride Law Firm with support contributed by Andrew and Tristan Tate.

What did the Stanford Nature Medicine ibogaine study show?

Published November 2023, the Stanford study on Special Operations veterans treated with ibogaine and 5-MeO-DMT in Mexico showed 88% reduction in PTSD symptoms, 87% reduction in depression, and 81% reduction in anxiety at one-month follow-up, along with significant improvements in executive function and cognitive performance. No serious cardiac adverse events were observed in a cardiac-screened population.

Why is synthetic noribogaine being patented while natural ibogaine is prosecuted?

Natural ibogaine, as a plant-derived alkaloid occurring in nature, cannot be patented. Noribogaine, its synthetic metabolite with a longer half-life, can be patented because it can be synthesized in a lab. Pharmaceutical companies including ATAI Life Sciences and DemeRx hold patents on noribogaine and related synthetic derivatives. This creates an economic incentive to regulate natural ibogaine out of access while funneling the patient population into patented synthetics.

Which political figures support ibogaine legalization?

Former Texas Governor and Trump-era Secretary of Energy Rick Perry; Robert F. Kennedy Jr.; Navy SEAL Republican Congressman Dan Crenshaw; Marine Corps three-star general Jack Bergman; former Kentucky Opioid Abatement Chair W. Bryan Hubbard; podcast host joe rogan. This coalition spans Trump-aligned Republicans, independents, and bipartisan military veterans.

Do you still plan to do a full flood-dose ibogaine session?

Yes. Under Ameen’s direct supervision. Not in a hospital. Not with a physician who lacks personal experience of the molecule. The supervision I trust is built on years of direct protocol knowledge, personal experience, and documented outcomes — not on institutional credentialing in a system that prohibits learning this molecule in the first place.

Next Time

The Texas state legislature moves on the $50 million ibogaine research bill in the first half of next year. That bill passing would be a political turning point I think most Americans won’t fully appreciate. I’ll cover it.

If the plea-deal pressure on Ameen escalates and he is forced into a sentence, I’ll cover that too. I will not let my friend be quietly disappeared into the federal prison system while the same political establishment that is prosecuting him starts funding research on the molecule he devoted his life to.

Stay on this. The tide is turning.

— tony huge